These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 26738328)

  • 1. [Combination therapy of Xipayimaizipizi Capsules and Tamsulosin for benign prostatic hyperplasia].
    Wang J; Xiao Y; Wang ZG; Wang FF; Cui XJ
    Zhonghua Nan Ke Xue; 2015 Nov; 21(11):1005-9. PubMed ID: 26738328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
    Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
    BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy of combination therapy of tamsulosin and solifenacin for mild and moderate benign prostatic hyperplasia with overactive bladder].
    Gao ZW; Xin SY; Zhang JG; Ren XQ; Shang YF; Zhang W; Li HB; Xiao F; Shao CS
    Zhonghua Nan Ke Xue; 2014 Mar; 20(3):239-43. PubMed ID: 24738461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of combined therapy with tamsulosin hydrochloride and meloxicam in patients with benign prostatic hyperplasia symptoms and impact on nocturia and sleep quality.
    Gorgel SN; Sefik E; Kose O; Olgunelma V; Sahin E
    Int Braz J Urol; 2013; 39(5):657-62. PubMed ID: 24267123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cardura monotherapy versus combination therapy of cardura and tolterodine L-tartrate tablets for II° ? benign prostatic hyperplasia with overactive bladder].
    Wang YY; Shi GW; He JY; Zhang YB
    Zhonghua Nan Ke Xue; 2013 Dec; 19(12):1099-102. PubMed ID: 24432622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Medium-to-long-term Use of Tolterodine Extended Release with or without Tamsulosin in Patients with Benign Prostate Hyperplasia and Larger Prostate Size: A Double-blind, Placebo-controlled, Randomized Clinical Trial.
    Cai JL; Zhou Z; Yang Y; Yan YF; Jing S; Na YQ
    Chin Med J (Engl); 2016 Dec; 129(24):2899-2906. PubMed ID: 27958220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Combination of tamsulosin and tolterodine alleviates refractory lower urinary tract symptoms in male patients].
    Sun YM; Gu WD; Lü JW; Leng J; Bo JJ; Liu DM
    Zhonghua Nan Ke Xue; 2010 Sep; 16(9):790-3. PubMed ID: 21171261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Longbishu Capsule combined with mesylate doxazosin: an efficacious therapy for benign prostatic hyperplasia].
    Chang DG; Li GS; Peng CH; Yu XJ; Zhang PH; Bi MS; Chen DA; You YD; Yang XZ
    Zhonghua Nan Ke Xue; 2015 Feb; 21(2):165-9. PubMed ID: 25796693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Ningmitai Capsules relieve lower urinary tract symptoms in patients with benign prostatic hyperplasia : A short-term clinical observation].
    Deng ZX; Ji LX; Zhang YR; Li CD; Cai J; Jiang HH
    Zhonghua Nan Ke Xue; 2018 Janurary; 24(1):72-77. PubMed ID: 30157365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Combination of tolterodine and tamsulosin for benign prostatic hyperplasia].
    Wu ZL; Geng H
    Zhonghua Nan Ke Xue; 2009 Jul; 15(7):639-41. PubMed ID: 19694381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men.
    Kawabe K; Yoshida M; Homma Y;
    BJU Int; 2006 Nov; 98(5):1019-24. PubMed ID: 16945121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Becher E; Miñana B; Mirone V; Castro R; Wilson T; Montorsi F;
    Eur Urol; 2009 Feb; 55(2):461-71. PubMed ID: 19013011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study.
    Bechara A; Romano S; Casabé A; Haime S; Dedola P; Hernández C; Rey H
    J Sex Med; 2008 Sep; 5(9):2170-8. PubMed ID: 18638006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial.
    Roehrborn CG; Barkin J; Siami P; Tubaro A; Wilson TH; Morrill BB; Gagnier RP
    BJU Int; 2011 Mar; 107(6):946-54. PubMed ID: 21332630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical impact of tamsulosin on generic and symptom-specific quality of life for benign prostatic hyperplasia patients: using international prostate symptom score and Rand Medical Outcomes Study 36-item Health Survey.
    Suzuki H; Yano M; Awa Y; Nakatsu H; Egoshi K; Mikami K; Ota S; Okano T; Hamano S; Ohki T; Furuya Y; Ichikawa T
    Int J Urol; 2006 Sep; 13(9):1202-6. PubMed ID: 16984553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart(®) ) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment-naïve men with moderately symptomatic benign prostatic hyperplasia: 2-year CONDUCT study results.
    Roehrborn CG; Oyarzabal Perez I; Roos EP; Calomfirescu N; Brotherton B; Wang F; Palacios JM; Vasylyev A; Manyak MJ
    BJU Int; 2015 Sep; 116(3):450-9. PubMed ID: 25565364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
    Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z
    BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Murraya koenigii- and Tribulus terrestris-based oral formulation versus tamsulosin in the treatment of benign prostatic hyperplasia in men aged >50 years: a double-blind, double-dummy, randomized controlled trial.
    Sengupta G; Hazra A; Kundu A; Ghosh A
    Clin Ther; 2011 Dec; 33(12):1943-52. PubMed ID: 22177370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Our experience with the treatment of benign prostatic hyperplasia (BPH) with tamsulosin.
    Cervenakov I; Fillo J
    Bratisl Lek Listy; 2001; 102(3):138-41. PubMed ID: 11433602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, placebo-controlled study to assess safety and efficacy of vardenafil 10 mg and tamsulosin 0.4 mg vs. tamsulosin 0.4 mg alone in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.
    Gacci M; Vittori G; Tosi N; Siena G; Rossetti MA; Lapini A; Vignozzi L; Serni S; Maggi M; Carini M
    J Sex Med; 2012 Jun; 9(6):1624-33. PubMed ID: 22510238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.